Paradigm Biopharmaceuticals Limited
P86.F
0.13 EUR
1 Tag: +7.63% (+0.01 EUR)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer P86.F
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Aktuelle News
-
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
Vorschau anzeigen
The osteoarthritis market is projected to grow from 2026 to 2036, driven by an aging population and rising disease prevalence. The expected launch of emerging therapies such as LEVI-04 (Levicept), ZILOSUL (Paradigm Biopharmaceuticals), TissueGene-C (TG-C) (Kolon TissueGene), AMZ001 (Amzell), SAR446959 (Sanofi), PCRX-201 (enekinragene inzadenovec) (Pacira BioSciences), and others is further supporting market expansion.New York, USA, June 15, 2026 (GLOBE NEWSWIRE) -- Osteoarthritis Market Expected
-
Market Sentiment Around Loss-Making Paradigm Biopharmaceuticals Limited (ASX:PAR)
Vorschau anzeigen
With the business potentially at an important milestone, we thought we'd take a closer look at Paradigm...
-
Could Paradigm Biopharmaceuticals’ (ASX:PAR) Leadership Presence Signal a Shift in Its Growth Story?
Vorschau anzeigen
Paradigm Biopharmaceuticals Limited recently presented at the Ignite Investment Summit, held from October 15 to October 16, 2025, at The Grand Ballroom, Grand Hyatt Hong Kong, featuring a presentation by Founder and Executive Chairman Paul John Rennie. This high-profile summit appearance drew attention to anticipated updates from Paradigm Biopharmaceuticals’ leadership, which could influence perceptions of the company’s outlook. We’ll review how investor anticipation of new insights from...
-
Paradigm Biopharmaceuticals (ASX:PAR): Exploring Valuation as Leadership Prepares for Ignite Investment Summit Presentation
Vorschau anzeigen
Paradigm Biopharmaceuticals (ASX:PAR) is drawing investor attention this week as its founder and executive chairman, Paul John Rennie, is set to present at the Ignite Investment Summit in Hong Kong. Events like these often prompt curiosity about possible updates or strategic direction from company leadership. See our latest analysis for Paradigm Biopharmaceuticals. Paradigm Biopharmaceuticals has seen momentum build sharply in recent weeks, with a 1-month share price return of 55% and a...
-
Weekly Picks: 🇺🇸 A Hedge Against US Government Shutdown And 2 More Picks
Vorschau anzeigen
This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos